ADMA logo

ADMA
Adma Biologics Inc

20,718
Mkt Cap
$2.62B
Volume
4.22M
52W High
$25.67
52W Low
$7.21
PE Ratio
18.80
ADMA Fundamentals
Price
$11.26
Prev Close
$11.08
Open
$11.08
50D MA
$13.07
Beta
1.29
Avg. Volume
8.9M
EPS (Annual)
$0.60
P/B
5.61
Rev/Employee
$788,520.87
$4,459.32
Loading...
Loading...
News
all
press releases
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About...
PR Newswire·9h ago
News Placeholder
More News
News Placeholder
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA vs. Takeda: surging Asceniv demand boosts ADMA, but Takeda's diversified portfolio and stronger returns make it the steadier pick now.
Zacks·1d ago
News Placeholder
RHHBY's Q1 Results Hit by Currency Headwinds, Sales Up 6% at CER
Roche's Q1 beat masks currency drag as strong drug demand drives CER growth and offsets biosimilar hit to legacy portfolio.
Zacks·2d ago
News Placeholder
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates and durable benefit, alongside a new FDA filing for ozekibart in chondrosarcoma.
Zacks·2d ago
News Placeholder
Roche Highlights Gazyva Progress, Reports Data on Enspryng, MS Drug
RHHBY's Gazyva gets FDA review for lupus as strong trial data and pipeline wins across neurology and MS bolster growth outlook.
Zacks·3d ago
News Placeholder
Will Asceniv Deliver for ADMA in the Upcoming Quarterly Results?
ADMA banks on surging Asceniv demand to sustain growth, supported by expanded plasma supply and broader coverage, which should drive continued gains into 2026.
Zacks·3d ago
News Placeholder
NVO's Etavopivat Hits Key Goals in Phase III Sickle Cell Disease Study
Novo Nordisk's etavopivat meets phase III goals, cutting VOCs and boosting haemoglobin in sickle cell disease, with data backing a favorable safety profile.
Zacks·4d ago
News Placeholder
LLY to Buy Oncology Biotech Kelonia Therapeutics for $7 Billion
Eli Lilly is set to acquire Kelonia Therapeutics in a $7B deal, boosting its genetic medicine platform with a novel in vivo CAR-T therapy for cancer.
Zacks·4d ago
News Placeholder
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues Shareholders Who Lost Money Urged to ContactGlancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues itsinvestigation on behalf of ADMA Biologics, Inc. (ADMA or the Company) (NASDAQ:ADMA) investors...
Business Wire·5d ago
News Placeholder
ADMA Biologics, Inc. (ADMA) ShareholdersWho Lost Money ContactLaw Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smithcontinues its investigation on behalf ofADMA Biologics, Inc. (ADMA or the Company) (NASDAQ:ADMA) investors concerning the Companys possible violations of federal...
Business Wire·5d ago
<
1
2
...
>

Latest ADMA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.